Chao Deng

Dr. Chao Deng

Wuxi School of Medicine, Jiangnan University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YWYalin Wang
Yalin Wang
XJXingming Ji
Xingming Ji
MYMeilin Yan
Meilin Yan
XCXue Chen
Xue Chen
MKMingzhu Kang
Mingzhu Kang
CDChao Deng
Chao Deng

1 April 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YWYalin Wang
Yalin Wang
LLLi Lai
Li Lai
LTLiping Teng
Liping Teng
YLYuhong Li
Yuhong Li
JCJianqing Cheng
Jianqing Cheng
CDChao Deng
Chao Deng

19 November 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HZHongyao Zhong
Hongyao Zhong
HZHuanxiao Zhang
Huanxiao Zhang
YHYiwei Hu
Yiwei Hu
SHShoukai He
Shoukai He
HQHuiting Qu
Huiting Qu
CDChao Deng
Chao Deng

15 March 2024 in Journal of Applied Biomedicine
Verified
Journal Article
Open access
PDF file
YLYouyi Liu
Youyi Liu
HZHuanxiao Zhang
Huanxiao Zhang
YLYuxuan Li
Yuxuan Li
HZHanqian Zha
Hanqian Zha
YGYujie Gao
Yujie Gao
CDChao Deng
Chao Deng
Dictyophora indusiata, commonly known as bamboo fungus, is a type of edible mushroom that is highly popular worldwide for its rich flavor and nutritional value. It is also recognized for its pharmaceutical efficacy, with medicinal benefits att...

20 October 2025 in Gut
Verified
Journal Article
Closed access
PDF file
KWKewei Wang
Kewei Wang
CXChen-Jun Xie
Chen-Jun Xie
ZDZheng Ding
Zheng Ding
TSTing Shan
Ting Shan
ZZZhangfeng Zhong
Zhangfeng Zhong
CDChao Deng
Chao Deng
Background: Gastric cancer (GC) ranks among the most prevalent lethal tumours globally. Cancer-associated fibroblasts (CAFs) are pivotal in creating an immunosuppressive tumour microenvironment (TME) in GC. Objective: Identifying a critical subpopulation of CAFs in promoting an immunosuppressive TME and enabling immune evasion, which may influence therapeutic effectiveness of immune checkpoint inhibitors (ICIs) for GC. Design: We performed single-cell RNA sequencing on 24 patients with GC and spatial transcriptomic profiling on formalin-fixed paraffin-embedded tissue sections from patients and controls. Integrating these data, we mapped cell types and gene signatures and identified distinct CAF subpopulations in the TME that influenced immunotherapy response in patients with GC. In vitro and in vivo studies further elucidated the molecular mechanisms, enhancing therapeutic implications. Results: In patients with GC, phosphodiesterase type 5A (PDE5A) expression was associated with shorter overall survival and the formation of immunosuppressive TME. We identified PDE5A + CAFs that were associated with TME alterations, including T cell exclusion and reduced CD8 + cytotoxic T lymphocyte infiltration, potentially impairing the efficacy of immunotherapy in GC. PDE5A + CAFs were observed to promote the epithelial–mesenchymal transition of GC cells through remodelling extracellular matrix. Furthermore, PDE5A + CAFs, via triggering of the PI3K/AKT/mTOR signalling pathway, released CXCL12, which engaged the CXCR4 receptor, consequently recruiting CD8 + TEX + LAG3 T cells to facilitate the development of immunosuppressive TME. The combined treatment of LAG3 blockade and PDE5A inhibitor vardenafil effectively enhanced immunotherapy responses, significantly curbing GC progression in mouse models. Conclusions: Our study elucidates the intricate role of PDE5A + CAFs in shaping the immunosuppressive TME in GC, providing mechanistic insights and therapeutic potential for combating this aggressive malignancy.

7 September 2022 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
YLYouyi Liu
Youyi Liu
XZXiading Zhang
Xiading Zhang
YHYiwei Hu
Yiwei Hu
MKMingzhu Kang
Mingzhu Kang
YWYibo Wu
Yibo Wu
CDChao Deng
Chao Deng
Emerging evidence has indicated that mesenchymal stem cells (MSCs) are involved in the modulation of inflammation. Human placenta‑derived (HPL)‑MSCs exist in sufficient quantities and play a role in immune regulation. However, the exact roles of HPL‑MSCs in inflammation and the specific underlying mechanisms are not well defined. In the present study, HPL‑MSCs were obtained from human fetal placentas, and further purified using a commercial kit. Using ELISA, reverse transcription‑quantitative PCR, western blot, NO detection and other assays, the present study revealed that HPL‑MSCs may improve lipopolysaccharide‑induced macrophage inflammation by regulating macrophage polarization. Further mechanistic studies demonstrated that HPL‑MSCs attenuated the NF‑κB signaling pathway by regulating the expression of toll‑like receptor 4 and the phosphorylation of IκBα and p65, which resulted in a reduction in the levels of inflammation. The present study indicated that HPL‑MSCs may act as a novel target for the treatment of inflammation‑related diseases.